AML1-MTG8 antibody
| Antigen | AML1-MTG8 |
| Clonality | Polyclonal |
| Host |
Rabbit |
| Reactivity |
Human |
| Application |
Immunohistochemistry (IHC)
|
![]() |
9 references available |
| Catalog no. | ABIN965546 |
| Quantity | 0.1mg |
| Price | 288.75 $ Plus shipping costs $45.00 |
| Shipping to |
|
| Availability | Will be delivered in 5 to 7 Business Days |
Additional Information
| Immunogen | Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to C-terminal residues of human AML1-MTG8(acute myelogenous leukemia 1 translocation 1 protein isoform MTG8c) |
| Description | AML1-MTG8(acute myelogenous leukemia 1 translocation 1 protein isoform MTG8c) is a putative zinc finger transcription factor and oncoprotein. In acute myeloid leukemia, especially in the M2 subtype, the t(8,21)(q22,q22) translocation is one of the most frequent karyotypic abnormalities. The translocation produces a chimeric gene made up of the 5'-region of the RUNX1 gene fused to the 3'-region of this gene. The chimeric protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation. Several transcript variants encoding multiple isoforms have been found for this gene. |
Application Details
| Application Notes | ELISA, Western blotting: 1µg/ml for 2hrs. |
| Purification | Purified by antigen-specific affinity chromatography. |
| Buffer | This antibody is stored in PBS, 50% glycerol |
| Preservative | 0.01% Sodium Azide |
| Storage | Store at -20°C. |
| Restrictions | For Research Use only |
Publications
| Product |
Tonks, Pearn, Tonks et al.: "The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells." in: Blood, Vol. 101, Issue 2, pp. 624-32, 2003 (PubMed).
Follows, Tagoh, Lefevre et al.: "Epigenetic consequences of AML1-ETO action at the human c-FMS locus." in: The EMBO journal, Vol. 22, Issue 11, pp. 2798-809, 2003 (PubMed). McGhee, Bryan, Elliott et al.: "Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism." in: Journal of cellular biochemistry, Vol. 89, Issue 5, pp. 1005-18, 2003 (PubMed). Chevallier, Corcoran, Lennon et al.: "ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein." in: Blood, Vol. 103, Issue 4, pp. 1454-63, 2004 (PubMed). Martinez, Drescher, Riehle et al.: "The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells." in: BMC cancer, Vol. 4, pp. 44, 2004 (PubMed). Zhang, Kalkum, Yamamura et al.: "E protein silencing by the leukemogenic AML1-ETO fusion protein." in: Science (New York, N.Y.), Vol. 305, Issue 5688, pp. 1286-9, 2004 (PubMed). Lausen, Cho, Liu et al.: "The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO." in: The Journal of biological chemistry, Vol. 279, Issue 47, pp. 49281-8, 2004 (PubMed). Lindberg, Olsson, Persson et al.: "The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation." in: Experimental hematology, Vol. 33, Issue 2, pp. 189-98, 2005 (PubMed). Liu, Shen, Huynh et al.: "Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia." in: Cancer research, Vol. 65, Issue 4, pp. 1277-84, 2005 (PubMed). |




